Fragment-Screen aims to enhance modern approaches to lead-drug development by optimising fragment-based drug discovery (FBDD). FBDD is a revolutionary approach to initiate drug discovery campaigns that greatly benefits from structural biology insight. While traditional drug discovery optimises complex chemical molecules binding with high affinity after screening of hundreds of thousands of molecules, FBDD aims to discover very small chemical entities (fragments) in focussed libraries containing from hundreds to not more than a few 1000 molecules. These fragments bind the specific target with low affinity but provide original, chemically tractable starting points for generating lead drugs by extending or joining fragments. FBDD has already generated drugs that have entered the clinic and even FDA approval.